BiotechTube

Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label

Phase 3Active
0 watching 0 views this week๐Ÿ“ˆ Rising
77
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hormone Sensitive Prostate Cancer

Conditions

Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate

Trial Timeline

Dec 17, 2014 โ†’ Sep 19, 2026

NCT ID
NCT02319837

About Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label

Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label is a phase 3 stage product being developed by Astellas Pharma for Hormone Sensitive Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02319837. Target conditions include Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02319837Phase 3Active

Competing Products

20 competing products in Hormone Sensitive Prostate Cancer

See all competitors
ProductCompanyStageHype Score
SomatropinEli LillyPhase 3
77
Somatropin (recombinant deoxyribonucleic acid [rDNA] origin)Eli LillyPre-clinical
23
Datopotamab Deruxtecan (Dato-DXd) + Steroid Containing MouthwashDaiichi SankyoPhase 1
33
Enzalutamide + Placebo + Androgen deprivation therapy (ADT)Astellas PharmaPhase 3
77
EnzalutamideAstellas PharmaPhase 2
52
Enzalutamide + PlaceboAstellas PharmaPhase 3
77
YM598Astellas PharmaPhase 2
52
pegylated Somatropin + pegylated Somatropin + Jintropin AQSun PharmaceuticalPhase 2
52
PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropin + PEG-somatropinSun PharmaceuticalApproved
85
PEG-somatropinSun PharmaceuticalPhase 3
77
ONO-4578 + letrozole + Palbociclib + abemaciclibOno PharmaceuticalPhase 1
33
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Trastuzumab + Fulvestrant + Standard of Care Single Agent ChemotherapyEli LillyPhase 2
52
Somatropin + SomatropinEli LillyPhase 3
77
Abemaciclib + Aromatase Inhibitor + Abemaciclib + FulvestrantEli LillyApproved
85
dalpiciclib isethionate tablets; abiraterone acetate tablets; prednisone tablets + placebo; abiraterone acetate tablets; prednisone tabletsJiangsu Hengrui MedicinePhase 1
33
SHR6390 + placeboJiangsu Hengrui MedicinePhase 3
77
SHR7280 tablets + SHR7280 dry suspensionJiangsu Hengrui MedicinePhase 1
33
SHR7280Jiangsu Hengrui MedicinePhase 1
33

Other Products from Astellas Pharma

Tacrolimus, PrografยฎApproved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Mysleeยฎ) + placeboApproved
85
TacrolimusApproved
85